IRIS
CAVAZZONI, Andrea
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.198
AS - Asia 7.062
EU - Europa 5.463
SA - Sud America 989
AF - Africa 381
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 6
Totale 22.109
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.042
SG - Singapore 2.535
CN - Cina 1.972
VN - Vietnam 1.170
IT - Italia 1.139
FI - Finlandia 819
IE - Irlanda 789
BR - Brasile 772
SE - Svezia 704
DE - Germania 545
HK - Hong Kong 520
UA - Ucraina 344
FR - Francia 279
ZA - Sudafrica 233
NL - Olanda 222
TR - Turchia 171
IN - India 158
GB - Regno Unito 154
RU - Federazione Russa 126
CA - Canada 91
AT - Austria 84
BE - Belgio 79
AR - Argentina 77
CI - Costa d'Avorio 68
BD - Bangladesh 66
IQ - Iraq 46
JP - Giappone 46
PL - Polonia 46
PK - Pakistan 45
KR - Corea 41
MX - Messico 41
EC - Ecuador 40
ID - Indonesia 39
ES - Italia 36
CO - Colombia 35
PH - Filippine 35
TH - Thailandia 27
CZ - Repubblica Ceca 22
JO - Giordania 21
LT - Lituania 20
MA - Marocco 20
VE - Venezuela 20
UZ - Uzbekistan 18
EG - Egitto 16
AE - Emirati Arabi Uniti 15
SA - Arabia Saudita 15
IR - Iran 14
KE - Kenya 14
AZ - Azerbaigian 12
CL - Cile 12
PS - Palestinian Territory 11
BO - Bolivia 9
JM - Giamaica 9
LB - Libano 9
MY - Malesia 9
IL - Israele 8
PE - Perù 8
PY - Paraguay 8
TN - Tunisia 8
AL - Albania 7
OM - Oman 7
SY - Repubblica araba siriana 7
TW - Taiwan 7
UY - Uruguay 7
AU - Australia 6
KG - Kirghizistan 6
KZ - Kazakistan 6
LU - Lussemburgo 6
NP - Nepal 6
DZ - Algeria 5
MD - Moldavia 5
RO - Romania 5
DO - Repubblica Dominicana 4
ET - Etiopia 4
HU - Ungheria 4
NZ - Nuova Zelanda 4
CH - Svizzera 3
EU - Europa 3
HR - Croazia 3
PA - Panama 3
QA - Qatar 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
BG - Bulgaria 2
BH - Bahrain 2
CR - Costa Rica 2
CY - Cipro 2
EE - Estonia 2
GA - Gabon 2
GE - Georgia 2
HN - Honduras 2
KW - Kuwait 2
LK - Sri Lanka 2
LV - Lettonia 2
MK - Macedonia 2
PT - Portogallo 2
TG - Togo 2
TJ - Tagikistan 2
Totale 22.087
Salva come PNG Salva come JPEG
Città #
Singapore 1.313
Ashburn 896
Dallas 824
Dublin 788
Chandler 744
San Jose 669
Ann Arbor 509
Santa Clara 491
Hong Kong 480
Beijing 458
Jacksonville 380
Parma 376
Ho Chi Minh City 345
Dearborn 281
Hanoi 257
Boardman 239
Johannesburg 223
Los Angeles 184
Nanjing 179
New York 177
Shanghai 169
Munich 164
Lauterbourg 150
Princeton 135
Izmir 133
San Mateo 113
Hefei 111
Milan 93
Bremen 86
Helsinki 86
Wilmington 84
São Paulo 81
Nanchang 72
Vienna 69
Abidjan 68
Brussels 62
Buffalo 61
Moscow 60
Da Nang 58
Shenyang 58
Kunming 56
Council Bluffs 55
Chicago 53
Haiphong 53
Marseille 53
Des Moines 52
The Dalles 51
Hebei 49
Jinan 49
Frankfurt am Main 47
Toronto 44
Tianjin 43
Columbus 41
Bologna 40
Guangzhou 39
Modena 39
Woodbridge 38
Turku 37
Amsterdam 35
Houston 35
Tokyo 35
Seattle 33
Warsaw 32
Changsha 30
Jiaxing 29
London 27
Pune 27
Stockholm 27
Rio de Janeiro 25
Denver 23
Jakarta 22
Redmond 22
Atlanta 20
Brooklyn 20
Rome 20
Seoul 20
Wayne 20
Montreal 19
Norwalk 19
Nuremberg 19
Quito 19
Reggio Emilia 19
Amman 18
Chennai 18
Manchester 18
Dhaka 17
New Delhi 17
Phoenix 17
Poplar 17
Tashkent 17
Augusta 16
Orem 16
Zhengzhou 16
Belo Horizonte 15
Boston 15
Brasília 15
Fremont 15
Baghdad 14
Biên Hòa 14
Campinas 14
Totale 13.451
Salva come PNG Salva come JPEG
Nome #
Balancing reactivity and antitumor activity: heteroarylthioacetamide derivatives as potent and time-dependent inhibitors of EGFR 350
Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines 258
Efficacy of the cdk4/6 dual inhibitor abemaciclib in egfr-mutated nsclc cell lines with different resistance mechanisms to osimertinib 246
PD-L1 overexpression induces STAT signaling and promotes the secretion of pro-angiogenic cytokines in non-small cell lung cancer (NSCLC) 242
Targeting glucosylceramide synthase induces antiproliferative and proapoptotic effects in osimertinib-resistant NSCLC cell models 239
Polymeric films loaded with cisplatin for malignant pleural mesothelioma: a pharmacokinetic study in an ovine model 221
Pemetrexed enhances membrane PD-L1 expression and potentiates T cell-mediated cytotoxicity by anti-PD-L1 antibody therapy in non-small-cell lung cancer 210
Irreversible Inhibition of Epidermal Growth Factor Receptor Activity by 3-Aminopropanamides. 209
Isolation and characterization of circulating tumor cells in advanced squamous-cell carcinoma of the lung 206
5-Benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity 205
Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells 198
Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC 193
5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line 191
Characterization of gefitinib uptake in NSCLC cell lines 189
CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells 189
Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells. 188
Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method 184
Enhancement of the anti-tumor activity of FGFR1 inhibition in squamous cell lung cancer by targeting downstream signaling involved in glucose metabolism. 182
Compatible osmolytes modulate the response of porcine endothelial cells to hypertonicity and protect them from apoptosis 181
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance 180
Targeting PI3K somatic mutations reduces invasion and EMT in squamous cell carcinoma of the lung 180
Anti-proliferative effect of letrozole and sorafenib in MCF-7/AROM-1 breast cancer cells 179
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 179
CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells 177
Creatine as a compatible osmolyte in muscle cells exposed to hypertonic stress 177
Novel Irreversible Epidermal Growth Factor Receptor Inhibitors by Chemical Modulation of the Cysteine-Trap Portion 176
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation 176
Anti-proliferative effect of combining Letrozole with Sorafenib in MCF-7/Arom-1 breast cancer cells 176
5-benzylidene-hydantoins as new inhibitors of cell proliferation 176
5-benzylidene-hydantoin UPR 1024 acts as EGFR inhibitor and induces DNA damage in A549 NSCLC cell line 175
Antiproliferative and proapototic effects of a new combi-molecule on non small cell lung cancer cell lines 174
Inhibition of PI3K Pathway Reduces Invasiveness and Epithelial-to-Mesenchymal Transition in Squamous Lung Cancer Cell Lines Harboring PIK3CA Gene Alterations. 173
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines 173
Epidermal growth factor receptor tyrosine kinase inhibitors: current status and future perspectives in the development of novel irreversible inhibitors for the treatment of mutant non-small cell lung cancer 172
Intrapleural polymeric devices containing Cisplatin for malignant pleural Mesothelioma in a rat tumor model: a preliminary study. 170
Dose-dependent effect of FHIT-inducible expression in Calu-1 lung cancer cell line 169
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification 169
Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines 168
Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands 168
Physicochemical and pharmacokinetic properties of polymeric films loaded with cisplatin for the treatment of malignant pleural mesothelioma 168
Corrigendum: CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells (Frontiers in Oncology, (2022), 12, (942341), 10.3389/fonc.2022.942341) 168
Acquired BRAF G469A Mutation as a Resistance Mechanism to First-Line Osimertinib Treatment in NSCLC Cell Lines Harboring an EGFR Exon 19 Deletion 167
Effect of inducible FHIT and p53 expression in the Calu-1 lung cancer cell line 166
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines 166
Effect of specific PI3K/mTOR inhibitors in squamous lung cancer cells carrying PI3K alterations 163
Intrapleural adjuvant treatment of mesothelioma : The combination of cisplatin-pemetrexed in rat tumor model 162
Isolation and characterization of H23 clones resistant to the KRASG12C inhibitors sotorasib and adagrasib 160
CDK4/6 INHIBITORS AS A NEW THERAPEUTIC APPROACH IN MESOTHELIOMA MODELS 158
Induction of BGT-1 and amino acid system A transport activities in endothelial cells exposed to hyperosmolarity 158
Cell culture studies of polysaccharide films loaded with cisplatin for the loco-regional therapy of malignant pleural mesothelioma 158
CDK4/6 inhibitors overcome resistance to osimertinib in NSCLC cell lines independently from resistance mechanisms 157
Anti-proliferative and pro-apoptotic effects of Sorafenib in breast cancer cells in vitro. 157
Meccanismo d’azione di UPR 1024: un nuovo farmaco con attività antiproliferativa in cellule di carcinoma polmonare umano 156
Aberrant expression of PTEN in squamous lung cancer cells: molecular analysis and impact on the synergistic combination of the targeted therapy with BKM120 and Defactinib 156
Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN 156
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines 154
Cancer of Unknown Primary: novel therapeutic opportunities from patient-derived cell cultures and in vivo models 154
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 153
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer 153
Effects of FGFR1 inhibition on survival, proliferation, and energy metabolism in Non Small Cell Lung Cancer (NSCLC) cell lines 152
Erlotinib enhances antibody-dependent cellular cytotoxicity of wil-type erlotinib-sensitive NSCLC cell lines 150
Osmotic regulation of ATA2 mRNA expression and amino acid transport system A activity 146
Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 145
Biological hallmarks and new therapeutic approaches for the treatment of pdac 145
Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones. (Cavazzoni and Bonelli co-first authors) 145
Coordinated inducible expression of p53 and FHIT has a strong anti proliferative effect in Calu-1 lung cancer cell line. 144
Epidermal Growth Factor Receptor Irreversible Inhibitors: Chemical Exploration of the Cysteine-Trap Portion 144
New strategies to overcome resistance to EGFR tyrosine kinase inhibitors in non small cell lung cancer 144
Mannich base derivatives as novel EGFR irreversible inhibitors 144
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 144
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines 142
Anti-proliferative effect of induced Fhit expression in non small cell lung cancer cell line (Calu-1) 140
Tumor-infiltrating lymphocytes and breast cancer: Beyond the prognostic and predictive utility 139
MYC Amplification as a Potential Mechanism of Primary Resistance to Crizotinib in ALK-Rearranged Non-Small Cell Lung Cancer: A Brief Report 139
New treatment opportunities in phosphatase and tensin homolo(PTen)-deficient tumors: Focus on PTen/focal adhesion kinase pathway 136
The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells 136
INCREASED SOLUBLE AND MEMBRANE-BOUND PD-L1 EXPRESSION IN NSCLC CELL LINES TREATED WITH PEMETREXED 135
Roles of compatible osmolytes and heat shock protein 70 in the induction of tolerance to stresses in porcine endothelial cells 132
Targeting FGFR1 pathway in non small cell lung cancer both in vitro and in vivo 132
Long-lasting inhibition of EGFR autophosphorylation in A549 tumor cells by intracellular accumulation of non-covalent inhibitors 132
Changes in glucose uptake after erlotinib treatment in NSCLC cell lines: a predictive and prognostic value? 132
Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells 131
PD-L1 OVEREXPRESSION INDUCES ANGIOGENIC CYTOKINE SECRETION AND ENDOTHELIAL CELL MIGRATION VIA STAT SIGNALLING. 130
Antibacterial and antitumor activity of tetracyclic fluoroquinolones with pyrido[2,3-a]carbazole structure 130
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib 130
Overcoming Palbociclib Resistance by Combined Treatment with PI3K/AKT/mTOR Inhibitors in Mesothelioma Cells 130
Irreversible EGFR inhibitor compounds with antiproliferative activity 129
Role of sphingolipid metabolism in osimertinib-resistance in EGFR-mutated NSCLC models 128
It Takes Two to Tango: Potential Prognostic Impact of Circulating TGF-Beta and PD-L1 in Pancreatic Cancer 127
Hypertonic stress and amino acid deprivation both increase expression of mRNA for amino acid transport system A 126
Synergistic activity of letrozole and sorafenib on MCF7/AROM-1 breast cancer cells 126
Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines 124
Effect of constitutive or inducible expression of the FHIT gene in a lung cancer cell line 124
New imidazo[2,1-b][1,3,4]thiadiazole aerivatives anhibit FAK phosphorylation and potentiate the antiproliferative effects of gemcitabine through modulation of the human equilibrative nucleoside transporter-1 in peritoneal mesothelioma 123
YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs 123
Intrapleural application of polymeric films containing cisplatin and pemetrexed in a rat tumour model of malignant pleural mesothelioma 121
Epidermal Growth Factor Receptor Intron-1 Polymorphism Predicts Gefitinib Outcome in Advanced Non-small Cell Lung Cancer 120
PD-L1 level is up-regulated in NSCLC cells after pemetrexed treatment 120
Targeting oncogenic PI3K/Akt/mTOR pathway in squamous cell lung carcinoma 120
Modulazione della riespressione del gene FHIT in cellule di carcinoma polmonare 119
Totale 16.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.022
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.022
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021292 0 0 0 0 0 0 0 0 0 38 205 49
2021/2022727 49 30 34 48 13 13 100 67 44 59 38 232
2022/20233.019 284 313 209 200 275 341 27 251 955 17 114 33
2023/20241.275 66 96 48 56 104 298 94 82 44 67 125 195
2024/20254.226 133 210 271 313 409 462 247 176 542 355 389 719
2025/20268.523 782 871 1.175 823 1.249 484 1.001 271 1.290 577 0 0
Totale 22.367